Variability of the dietary-derived CYP2D6 activity marker solanidine in vivo

被引：0
|
作者：
Mueller, J. P. [1 ]
Saromba, J. [1 ]
Ziegler, P. [2 ]
Tremmef', R. [3 ,4 ]
Rengelshausen, J. [2 ]
Schaeffeler, E. [3 ,4 ]
Just, K. S. [1 ]
Schwab, M. [3 ,5 ,6 ]
Kraus, T. [2 ]
Sting, J. C. [1 ]
机构：
[1] Univ Hosp RWTH Aachen, Inst Clin Pharmacol, Aachen, Germany
[2] Univ Hosp RWTH Aachen, Inst Occupat Social & Environm Med, Aachen, Germany
[3] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
[4] Univ Tubingen, Tubingen, Germany
[5] Univ Tubingen, Dept Clin Pharmacol, Tubingen, Germany
[6] Univ Tubingen, Dept Biochem & Pharm, Tubingen, Germany
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2024年 / 397卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P226
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [31] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
    Kiss, Adam Ferenc
    Toth, Katalin
    Juhasz, Cintia
    Temesvari, Manna
    Paulik, Jozsef
    Hirka, Gabor
    Monostory, Katalin
    MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
  • [32] In vivo indices of enzyme activity:: the effect of renal impairment on the assessment of CYP2D6 activity
    Rostami-Hodjegan, A
    Funck-Brentano, C
    Kroemer, HK
    Tucker, GT
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (05) : 577 - 578
  • [33] CYP2D6 Genotype and Tamoxifen Activity: Understanding Interstudy Variability in Methodological Quality
    Ratain, M. J.
    Nakamura, Y.
    Cox, N. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (02) : 184 - 186
  • [34] Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity
    Doki, Kosuke
    Sekiguchi, Yukio
    Kuga, Keisuke
    Aonuma, Kazutaka
    Homma, Masato
    DRUG METABOLISM AND PHARMACOKINETICS, 2015, 30 (04) : 257 - 262
  • [35] CYP2D6 expression is regulated by polymorphisms that affect splicing and trancription: new biomarkers for CYP2D6 activity
    Wang, Danxin
    Poi, Ming J.
    Sun, Xiaochun
    Gaedigk, Andrea
    Leeder, J. Steven
    Sadee, Wolfgang
    FASEB JOURNAL, 2013, 27
  • [36] Impact of CYP2D6*2, CYP2D6*35, rs5758550, and related haplotypes on risperidone clearance in vivo
    Storset, Elisabet
    Braten, Line Skute
    Ingelman-Sundberg, Magnus
    Johansson, Inger
    Molden, Espen
    Kringen, Marianne Kristiansen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (10) : 1531 - 1541
  • [37] Common mutant alleles of CYP2D6 causing the defect of CYP2D6 enzyme activity in a Japanese population
    Ishiguro, A
    Kubota, T
    Sasaki, H
    Yamada, Y
    Iga, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (04) : 414 - U3
  • [38] A novel CYP2D6 scoring system for the prediction of CYP2D6 activity: Application to tamoxifen metabolism.
    Borges, S.
    Li, L.
    Robarge, J.
    Nguyen, A.
    Azzouz, F.
    Desta, Z.
    Skaar, T.
    Flockhart, D. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S67 - S67
  • [39] In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine
    Xu, ZH
    Xie, HG
    Zhou, HH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (04) : 518 - 521
  • [40] The Effects of Puerarin on CYP2D6 and CYP1A2 Activities In Vivo
    Zheng, Jiao
    Chen, Bin
    Jiang, Bing
    Zeng, Ling
    Tang, Zhi-Rong
    Fan, Lan
    Zhou, Hong-Hao
    ARCHIVES OF PHARMACAL RESEARCH, 2010, 33 (02) : 243 - 246
12345